Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   37564   clinical trials with a EudraCT protocol, of which   6160   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2006-001363-31
    Sponsor's Protocol Code Number:M05-741
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2007-07-23
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2006-001363-31
    A.3Full title of the trial
    VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin System Inhibitors
    Studio multicentrico di fase II, prospettico, randomizzato, in doppio cieco verso placebo; per valutare la sicurezza e l`efficacia del Paracalcitolo capsule nel ridurre l`Albuminuria in soggetti nefropatici affetti da diabete di tipo 2 in trattamento con inibitori del sistema Renina-angiotensina
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberM05-741
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAbbott GmbH & Co KG
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameParacalcitol
    D.3.2Product code NA
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNParicalcitol
    D.3.9.1CAS number 131918611
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D. medicinal product typeNon Applicabile
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, soft
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Type 2 diabetic nephropathy
    Soggetti nefropatici affetti da diabete di tipo 2
    E.1.1.2Therapeutic area Diseases [C] - Hormonal diseases [C19]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10038444
    E.1.2Term Renal failure chronic
    E.1.2System Organ Class 10038359 - Renal and urinary disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The study objective is to evaluate the safety and efficacy of paricalcitol capsules on albuminuria reduction in Chronic Kidney Disease (CKD) subjects with Type 2 diabetic nephropathy receiving optimal ACEi and/or ARB therapy.
    L'obiettivo principale consiste nel valutare la sicurezza e l'efficacia del Paracalcitolo capsule nel ridurre l'Albuminuria in soggetti nefropatici affetti da diabete di tipo 2
    E.2.2Secondary objectives of the trial
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    A subject will be selected for study participation if he/she meets the following criteria:
    1.Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed.
    2.Male or female subjects ³ 20 years old.
    3.Subject has Type 2 Diabetes Mellitus and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the Screening Phase.
    4.Subject has been receiving stable dose (i.e., same type and regimen) of ACEi and/or ARB for at least three months prior to the Screening Phase. However, subject may have switched to different brands but at equivalent doses during the three months prior to the Screening Phase.
    5.Subject is not expected to begin dialysis for at least 6 months.
    6.If female, subject is not breast feeding or is not pregnant (verified by negative urine pregnancy test prior to the Treatment Phase); or is not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy); or is of childbearing potential and practicing one of the following methods of birth control:·Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)·Contraceptives (oral or parenteral) for three months prior to study drug administration·Maintains a monogamous relationship with a vasectomized partner·Total abstinence from sexual intercourse
    7.For entry in the Treatment Phase the subject must satisfy the following criteria based on the Screening laboratory values:·Estimated GFR between 25-75 mL/min/1.73m2 by simplified MDRD formula·UACR between 200 and 1800 mg/g as determined by the mean of the three first morning void urine specimens obtained within one week·Corrected serum calcium level £ 9.5 mg/dL·iPTH value between 50-500 pg/mL·HbA1c £ 1 Serum albumin > 3.0 g/dL·Negative urine pregnancy test for female subjects
    I pazienti potranno prendere parte allo studio se avranno soddisfatto i seguenti criteri:
    1.Il soggetto ha volontariamente firmato e datato il modulo di consenso informato, approvato dal Comitato etico indipendente, dopo aver ricevuto adeguate informazioni sulla natura della sperimentazione e dopo aver avuto l'opportunita' di porre domande. Il consenso informato va firmato prima di intraprendere una qualsiasi procedura specifica della sperimentazione.
    2.Individui di sesso maschile o femminile di eta' &#8805;&#61472;20.
    3.Il soggetto e' affetto da diabete mellito di tipo 2 ed e' stato trattato con almeno un farmaco anti-ipererglicemico nei 12 mesi precedenti la fase di screening.
    4.Il soggetto sta assumendo una dose stabile (vale a dire medesimo tipo e regime) di ACEi e/o ARB almeno da tre mesi precedenti la fase di screening; tuttavia, durante i tre mesi precedenti tale fase, il paziente, pur mantenendo dosi equivalenti, puo' essere passato a marchi differenti dello stesso principio attivo.
    5.Si prevede che il soggetto non debba essere sottoposto a dialisi per almeno 6 mesi.
    6.Se di sesso femminile, la paziente non dovra' allattare al seno o essere in stato di gravidanza (verificato attraverso la negativita' a un test di gravidanza sulle urine effettuato prima della fase di trattamento); oppure non dovra' essere potenzialmente fertile, cioe' dovra' essere in post-menopausa da almeno 1 anno od essere stata sottoposta a intervento chirurgico per indurre sterilita' (legatura bilaterale delle tube, ooforectomia bilaterale o isterectomia); oppure se potenzialmente fertile, dovra' praticare uno dei seguenti metodi di controllo delle nascite:
    ·Preservativi, spugne, schiume, gelatine, diaframmi o dispositivi intrauterini (IUD)
    ·Contraccettivi (orali o parenterali) per i tre mesi precedenti la somministrazione del medicinale sperimentale
    ·Mantenimento di una relazione monogama con un partner sottoposto a vasectomia
    ·Astinenza totale dai rapporti sessuali
    7.Per poter essere inserito nella fase di trattamento, il soggetto deve aver soddisfatto i seguenti criteri sulla base dei valori di laboratorio allo screening:
    ·GFR stimata tra 25 e 75 ml/min/1,73 m2 per mezzo della formula MDRD semplificata
    ·UACR tra 200 e 1800 mg/g, come stabilito dalla media di tre campioni di urine del mattino ottenuti nell'arco di una settimana
    ·Livello corretto del calcio sierico &#8804;&#61472;9,5 mg/dl
    ·Valore di iPTH compreso fra 50 e 500 pg/ml· HbA1c &#8804;&#61472;12%
    ·Albumina sierica &gt; 3,0 g/dl
    ·Negativita' al test di gravidanza delle urine
    E.4Principal exclusion criteria
    Subjects meeting the following criteria will be excluded from the study:
    1.Subject has been on prescription-based vitamin D therapy within the 6 months prior to the Screening Phase. 2.Subject has a history of an allergic reaction or significant sensitivity to paricalcitol or to drugs similar to the study drug.
    3.Subject has primary glomerulonephritis or secondary nephritis in addition to diabetic nephropathy.
    4.Subject has had acute renal failure within 12 weeks of the Screening Phase defined by an acute rise in serum creatinine (of at least 0.5 mg/dL or 44 mmol/L) to more than 4 mg/dL (350 mmol/L).
    5.Subject has chronic gastrointestinal disease, which in the Investigator's opinion may cause significant GI malabsorption.
    6.Subject has secondary hypertension (i.e., renal artery stenosis, primary aldosteronism or pheochromocytoma). 7.Subject has poorly controlled hypertension (systolic blood pressure ³ 160 mmHg and or diastolic blood pressure ³ 100 mmHg).
    8.Subject has a history of kidney stones.
    9.Subject has a history of drug or alcohol abuse within 6 months prior to the Screening Phase.
    10.Subject has evidence of poor compliance with diet or medication that may interfere, in the Investigator's opinion, with adherence to the protocol.
    11.Subject has received any investigational drug within 30 days prior to study drug administration. 12.Subject is taking calcitonin, bisphosphonates, cinacalcet, glucocorticoids (except topical glucocorticoids), or other drugs that may affect calcium or bone metabolism, other than calcium containing phosphate binder or female subjects on stable (same dose and product for 3 months) estrogen and/or progestin therapy.
    13.For any reason, subject is considered by the Investigator to be an unsuitable candidate to receive paricalcitol capsules or is put at risk by study procedures.
    14.Subject is known to be HIV positive.
    1.Al soggetto e' stata prescritta una terapia a base di vitamina D durante i 6 mesi precedenti la fase di screening.
    2.Il soggetto presenta una storia di reazioni allergiche o di sensibilita' significativa nei confronti del Paracalcitolo o di altri farmaci analoghi al medicinale sperimentale.
    3.Oltre alla nefropatia diabetica, il soggetto e' affetto da glomerulonefrite primaria o da nefrite secondaria.
    4.Il soggetto e' stato colpito da insufficienza renale acuta nelle 12 settimane precedenti la fase di screening, definita per mezzo di un innalzamento acuto della creatinina sierica (pari almeno a 0,5 mg/dl, o 44 mmoli/l) sino a piu' di 4 mg/dl (350 mmoli/l).
    5.Il soggetto e' affetto da malattia gastrointestinale cronica che, a parere dello sperimentatore, puo' determinare un malassorbimento significativo a livello GI.
    6.Il soggetto evidenzia ipertensione secondaria (vale a dire stenosi arteriosa renale, aldosteronismo primario o feocromocitoma
    7.Il soggetto ha un'ipertensione scarsamente controllata (pressione sanguigna sistolica &#8805;&#61472;160 mm Hg e/o pressione sanguigna diastolica &#8805;&#61472;100 mm Hg).).
    8.Il soggetto ha una storia di calcoli renali.
    9.Il soggetto ha una storia di abuso di droghe o di alcool nei 6 mesi precedenti la fase di screening
    10.Il soggetto presenta evidenze di scarsa compliance con la dieta o con medicinali che, a parere dello sperimentatore, possono interferire con l'adesione al protocollo.
    11.Al soggetto e' stato somministrato un qualsiasi medicinale sperimentale entro i 30 giorni precedenti la somministrazione del medicinale sperimentale.
    12.Il soggetto sta assumendo calcitonina, bisfosfonati, cinacalcet, glucocorticoidi (eccezion fatta per i glucocorticoidi ad uso topico), oppure altri farmaci che possono incidere sul metabolismo del calcio o delle ossa diversi da un chelante del fosforo contenente calcio, oppure si tratta di donne in terapia stabile (stessa dose e prodotto per 3 mesi) con estrogeni e/o progestinici.
    13.Lo sperimentatore ritiene che, per un qualunque motivo, il soggetto rappresenti un candidato non adatto all'assunzione di capsule di Paracalcitolo, oppure le procedure dello studio lo mettono in pericolo.
    14.E' nota una positivita' del soggetto all'HIV
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint will be the percent change from baseline to the last on-treatment UACR measurement using UACR levels determined from the first morning void urine collections
    consiste nel cambiamento in percentuale rispetto al basale dell'ultimo UACR in fase di trattamento utilizzando livelli di UACR determinati attraverso la raccolta delle prime urine della mattina dopo le 5.00
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other Yes
    E. description
    - Stesso farmaco ad altro dosaggio
    - same IMP used at different dosage
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Information not present in EudraCT
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last patient, last visit
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months13
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months16
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F. of other specific vulnerable populations
    donne in eta' fertile che assumono adeguati metodi contraccettivi
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 162
    F.4.2.2In the whole clinical trial 258
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-08-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-06-11
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2009-05-26
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice